BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 19885792)

  • 21. [Current ascites therapy].
    Ochs A
    Praxis (Bern 1994); 1997 Jan; 86(4):94-7. PubMed ID: 9064726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathogenesis and treatment of fluid and electrolyte imbalance in cirrhosis.
    Cárdenas A; Ginès P
    Semin Nephrol; 2001 May; 21(3):308-16. PubMed ID: 11320500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on peripheral arterial vasodilation, ascites and hepatorenal syndrome in cirrhosis.
    Knotek M; Rogachev B; Schrier RW
    Can J Gastroenterol; 2000 Nov; 14 Suppl D():112D-121D. PubMed ID: 11110623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of ascites in patients with liver cirrhosis without neither hyponatremia nor renal insufficiency. Results of a randomized study comparing diuretics and punctures compensated by albumin].
    Hagège H; Ink O; Ducreux M; Pelletier G; Buffet C; Etienne JP
    Gastroenterol Clin Biol; 1992; 16(10):751-5. PubMed ID: 1478401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathogenesis and treatment of ascites in hepatic cirrhosis.
    Gentilini P; La Villa G; Romanelli RG; Foschi M; Laffi G
    Cardiology; 1994; 84 Suppl 2():68-79. PubMed ID: 7954548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cirrhotic ascites: pathogenesis and management.
    Garcia-Tsao G
    Gastroenterologist; 1995 Mar; 3(1):41-54. PubMed ID: 7743121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacotherapy of ascites associated with cirrhosis.
    Ginès P; Arrovo V; Rodés J
    Drugs; 1992 Mar; 43(3):316-32. PubMed ID: 1374317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current management and novel therapeutic strategies for refractory ascites and hepatorenal syndrome.
    Suzuki H; Stanley AJ
    QJM; 2001 Jun; 94(6):293-300. PubMed ID: 11391027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical management of ascites and its complications.
    Wongcharatrawee S; Garcia-Tsao G
    Clin Liver Dis; 2001 Aug; 5(3):833-50. PubMed ID: 11565143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Rational diuretic therapy in patients with liver cirrhosis].
    Vogt B; Reichen J
    Ther Umsch; 2000 Jun; 57(6):355-60. PubMed ID: 10894019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites.
    Ginès A; Escorsell A; Ginès P; Saló J; Jiménez W; Inglada L; Navasa M; Clària J; Rimola A; Arroyo V
    Gastroenterology; 1993 Jul; 105(1):229-36. PubMed ID: 8514039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is there still a need for albumin infusions to treat patients with liver disease?
    Ginès P; Arroyo V
    Gut; 2000 May; 46(5):588-90. PubMed ID: 10764695
    [No Abstract]   [Full Text] [Related]  

  • 33. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.
    Schrier RW; Arroyo V; Bernardi M; Epstein M; Henriksen JH; Rodés J
    Hepatology; 1988; 8(5):1151-7. PubMed ID: 2971015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review: the controversy over the pathophysiology of ascites formation in cirrhosis.
    Wong F; Girgrah N; Blendis L
    J Gastroenterol Hepatol; 1997 Jun; 12(6):437-44. PubMed ID: 9195401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure.
    Ginès A; Salmerón JM; Ginès P; Arroyo V; Jiménez W; Rivera F; Rodés J
    J Hepatol; 1993 Feb; 17(2):220-6. PubMed ID: 8445236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ascites and hepatorenal syndrome during cirrhosis: two entities or the continuation of the same complication?
    Gentilini P; Laffi G; La Villa G; Romanelli RG; Blendis LM
    J Hepatol; 1999 Dec; 31(6):1088-97. PubMed ID: 10604585
    [No Abstract]   [Full Text] [Related]  

  • 37. Effective plasma volume in cirrhosis with ascites. Evidence that a decreased value does not account for renal sodium retention, a sponteneous reduction in glomerular filtration rate (GFR), and a fall in GFR during drug-induced diuresis.
    Lieberman FL; Ito S; Reynolds TB
    J Clin Invest; 1969 Jun; 48(6):975-81. PubMed ID: 5771197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The hepatorenal syndrome.
    Moore K
    Clin Sci (Lond); 1997 May; 92(5):433-43. PubMed ID: 9176015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ultrafiltration in diuretic-resistant volume overload in nephrotic syndrome and patients with ascites due to chronic liver disease.
    Davenport A
    Cardiology; 2001; 96(3-4):190-5. PubMed ID: 11805386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of cirrhotic ascites by dialytic ultrafiltration with a hemofilter system.
    Lai KN; Leung JW; Swaminathan R; Panesar NS
    Blood Purif; 1987; 5(4):252-5. PubMed ID: 3426828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.